What this study adds
Twice-daily (BID) dosing of MR309 provided a plasma PK profile with less fluctuation than once-daily dosing
A monotonic relationship between MR309 plasma concentration and brain σ1R occupancy was seen, but 200 mg BID did not achieve 75% σ1R occupancy required for maximal antinociception in animal models